1
|
Vazanova A, Jurecekova J, Balharek T, Marcinek J, Stasko J, Dzian A, Plank L, Zubor P, Racay P, Hatok J. Differential mRNA expression of the main apoptotic proteins in normal and malignant cells and its relation to in vitro resistance. Cancer Cell Int 2018. [PMID: 29515335 PMCID: PMC5836377 DOI: 10.1186/s12935-018-0528-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background Apoptosis plays an important role in the development and homeostasis of multicellular organisms and its deregulation may result in many serious diseases, including cancer. Now it is clear that some oncogenic mutations disrupt apoptosis, leading to tumour initiation, progression or metastasis. Here, expression of apoptotic genes in context of drug resistance was investigated. Methods We examined total of 102 samples from leukemic patients (n = 60) and patients with solid tumours (n = 42). We used RT-PCR to determine the levels of mRNA expression and the in vitro chemoresistance of leukemic cells was evaluated using the MTT assay. Results We found statistically significant increase in mRNA expression of all investigated proteins (p53, BAX, Bcl-2 and Bcl-XL) between the leukemia samples and leukocytes from healthy volunteers. We did not find any significant difference in mRNA levels among the solid tumour samples. Notably, we showed a significant positive correlation in both leukemic and solid tumour patient groups between p53 and BAX mRNA. We found that the highest values for the Bcl-2/BAX ratio were in solid tumours in comparison to leukemic cells or normal leukocytes. Moreover, we assessed the impact of p53 and BAX mRNA levels on the sensitivity of the leukemic cells to selected cytostatics. Conclusions Elevated levels of p53 and BAX mRNA may indicate cellular response to possible changes in genomic DNA integrity associated with malignant transformation. We suggest that the BAX gene is regulated by the p53 protein but the initiation of apoptosis through the transcription activation of BAX is blocked by the high levels of Bcl-2. Given that the apoptosis resistance mechanisms are different among oncological patients as well as stages of identical malignancy cases, personalized and specific combination therapy is proposed to be more effective in clinical application.
Collapse
Affiliation(s)
- Andrea Vazanova
- 1Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin (JFM), Comenius University in Bratislava (CU), Mala Hora 4D, 03601 Martin, Slovak Republic.,2Clinic of Haematology and Transfusiology, JFM CU and Martin University Hospital (MUH), Kollarova 2, Martin, Slovak Republic
| | - Jana Jurecekova
- 1Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin (JFM), Comenius University in Bratislava (CU), Mala Hora 4D, 03601 Martin, Slovak Republic.,Biomedical Center Martin, JFM CU, Mala Hora 4D, Martin, Slovak Republic
| | - Tomas Balharek
- Department of Pathologic Anatomy, JFM CU and MUH, Kollarova 2, Martin, Slovak Republic
| | - Juraj Marcinek
- Department of Pathologic Anatomy, JFM CU and MUH, Kollarova 2, Martin, Slovak Republic
| | - Jan Stasko
- 2Clinic of Haematology and Transfusiology, JFM CU and Martin University Hospital (MUH), Kollarova 2, Martin, Slovak Republic
| | - Anton Dzian
- Clinic of Thoracic Surgery, JFM CU and MUH, Kollarova 2, Martin, Slovak Republic
| | - Lukas Plank
- Department of Pathologic Anatomy, JFM CU and MUH, Kollarova 2, Martin, Slovak Republic
| | - Pavol Zubor
- Department of Obstetrics and Gynecology, CU JFM and MUH, Kollarova 2, Martin, Slovak Republic
| | - Peter Racay
- 1Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin (JFM), Comenius University in Bratislava (CU), Mala Hora 4D, 03601 Martin, Slovak Republic.,Biomedical Center Martin, JFM CU, Mala Hora 4D, Martin, Slovak Republic
| | - Jozef Hatok
- 1Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin (JFM), Comenius University in Bratislava (CU), Mala Hora 4D, 03601 Martin, Slovak Republic
| |
Collapse
|
2
|
Lundstrom K, Boulikas T. Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat 2004; 2:471-86. [PMID: 14529313 DOI: 10.1177/153303460300200513] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Gene therapy as part of modern molecular medicine holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a revolutionary era to cancer treatment. Gene therapy has been named the medicine of the future. For the past 10 years various viral and non-viral vectors have been engineered for improved gene and drug delivery. Although various diseases have been targeted, cancer therapy has been addressed to a large extent because of the straight forward approach. Delivery of toxic or immunostimulatory genes by viral and non-viral vectors has been investigated and encouraging results have been obtained in animal models. A large number of clinical trials have been conducted with some highly promising outcome. We propose that combinations of viruses with liposomes or polymers will solve the problem of systemic viral delivery and tumor targeting, bringing a revolution in molecular medicine and in applications of gene therapy in humans.
Collapse
Affiliation(s)
- Kenneth Lundstrom
- Regulon Inc./BioXtal, Chemin des Croisettes 22, CH-1066, Epalinges, Swizerland.
| | | |
Collapse
|
3
|
Abstract
p53, perhaps the single most important human tumor suppressor, is commonly mutated in human cancers. Normally genotoxic stress and hypoxia activate p53, which, through DNA-specific transcription activation, transcriptional repression, and protein-protein interactions, triggers cell cycle arrest and apoptosis. One of the genes induced by p53 was identified as that encoding the insulin-like growth factor binding protein (IGFBP)-3. IGFBP-3 was originally defined by the somatomedin hypothesis as the principal carrier of IGF-I in the circulation and the primary regulator of the amount of free IGF-I available to interact with the IGF-1 receptor. However, there is accumulating evidence that IGFBP-3 can also cause apoptosis in an IGF-independent manner. Thus, IGFBP-3 induction by p53 constitutes a new means of cross-talk between the p53 and IGF axes, and suggests that the ultimate function of IGFBP-3 may be to serve a protective role against the potentially carcinogenic effects of growth hormone and IGF-I.
Collapse
Affiliation(s)
- A Grimberg
- Division of Pediatric Endocrinology, The University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA
| |
Collapse
|
4
|
Choisy-Rossi C, Reisdorf P, Yonish-Rouach E. Mechanisms of p53-induced apoptosis: in search of genes which are regulated during p53-mediated cell death. Toxicol Lett 1998; 102-103:491-6. [PMID: 10022301 DOI: 10.1016/s0378-4274(98)00238-0] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The tumor suppressor gene p53 is a major player in the protection of cells from DNA damage. In the majority of human cancers, p53 is functionally inactivated--mostly by mutations but also by interaction with viral or cellular proteins. Wild-type p53 is involved in essential functions such as DNA repair, transcription, genomic stability, senescence, cell cycle control and apoptosis. It was shown to be a sequence-specific transcriptional activator, and this activity appears to be necessary to impose growth arrest. A major target gene which participates in p53-mediated growth arrest is p21/Waf1, an inhibitor of cyclin-dependent kinases. Whether or not transcriptional activation of target genes is required for p53-mediated apoptosis may depend on the cell type and external factors, and the mechanism of cell death induction is not clear yet. We have employed clones of the M1 myeloid leukemic cell line expressing a temperature-sensitive p53 mutant to study genes which are regulated during p53-induced apoptosis.
Collapse
Affiliation(s)
- C Choisy-Rossi
- Laboratoire de Cancérogenèse Moléculaire, UMR 217 du CNRS/CEA, DRR-DSV, Fontenay-aux-Roses, France
| | | | | |
Collapse
|